Explore Stanford technologies available for licensing:

Stanford scientists have discovered a novel approach to address cardiovascular complications resulting from cancer chemotherapy, particularly those caused by tyrosine kinase inhibitors (TKIs).

Stanford researchers have developed novel AsCas12a-expressing mouse models for simultaneous editing of multiple genomic loci in vivo with unique targeting capabilities relative to traditional Cas9 models, enabling the rapid creation of complex genotypes in somatic cells and ca

Stanford researchers have designed a electrochemical sensor system for continuous analyte measurement and tracking in complex biological samples (i.e. blood and serum) with a wide range of clinical and non clinical applications.

Researchers from Stanford developed recombinant polypeptide-cytokine conjugates and methods to induce antigen-specific regulatory T cells (Treg) for the treatment of inflammatory and autoimmune diseases.

Stanford researchers have developed recombinant polypeptides targeting growth factor beta (TGF-?) receptor 1 and TGF?

Stanford researchers have developed a high-throughput platform to engineer synthetic ETS transcription factors that enhance human T cell function beyond natural TFs, enabling precise and scalable cellular reprogramming for immunotherapy and other therapies.

Stanford researchers have developed a high-throughput platform that designs, delivers, and screens synthetic microRNAs to precisely reprogram human T cells and improve the efficacy of CAR T cell therapies.

Stanford researchers have developed a novel PET agent for diseases stemming from T cell origin. The probes help visualize the disease status as well as the progress of therapy.

Stanford scientists have developed a method and apparatus for simultaneously measuring mucus rheology and cilia activity on live airway cells without removing mucus or inhibiting cilia function.

Scientists at Stanford have developed a new method to manufacture sterile microbial food that contains levels of key bioactive metabolites derived from fermented foods.

Glaucoma results from the loss of retinal ganglion cells (RGCs), the primary output neurons of the retina that connect to brain areas responsible for vision. Current treatments focus on lowering intraocular pressure but do not prevent blindness in about 25% of patients.

Stanford researchers have developed an innovative, integrated diagnostic and therapeutic focused ultrasound (FUS) platform that non-invasively targets peripheral nerves to produce temporary, reversible nerve blockade for acute and chronic pain management.

Stanford scientists have discovered that theta oscillations in the anterior cingulate cortex can detect empathic states, and that targeting the upstream orexin circuit can modulate empathy-related behaviors.

High-grade gliomas, such as glioblastoma and diffuse midline glioma, are currently incurable diseases with an urgent need for novel therapeutic approaches.

Researchers at Stanford have developed constitutively active, programmable synthetic cytokine receptors capable of polarizing human macrophages to a variety of user-defined cell states which may be useful for therapeutic applications.